Treatment with intravenous remdesivir (a novel nucleotide analogue prodrug in development) was initiated on the evening of day 7, and no adverse events were observed in association with the infusion.

第 7 天晚上开始静脉注射瑞德西韦（一种正在开发的新型核苷酸类似物前药）治疗， 未观察到与输注相关的不良事件。